CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Industry Giants Say Covid-19 Offers A 'Significant Opportunity' To Fast-Track Cancer Eradication

Industry Giants Say Covid-19 Offers A...

Advantages of Biotech Partnership

Advantages of Biotech Partnership

How AI Enhances Biotech Operations

How AI Enhances Biotech Operations

What You Should Know About Biotechnology

What You Should Know About...

How Advanced Technologies Improves Clinical Trials

How Advanced Technologies Improves...

Why Create Patient Recruitment Strategies for Clinical Trials

Why Create Patient Recruitment...

Clinical Trials: Top Ways to Make Patient Recruitment Process More Efficient

Clinical Trials: Top Ways to Make...

Patient Recruitment: Some Excellent Strategies to Keep in Mind

Patient Recruitment: Some Excellent...

Industry Giants Say Covid-19 Offers A 'Significant Opportunity' To Fast-Track Cancer Eradication

Industry Giants Say Covid-19 Offers A...

Advantages of Biotech Partnership

Advantages of Biotech Partnership

How AI Enhances Biotech Operations

How AI Enhances Biotech Operations

What You Should Know About Biotechnology

What You Should Know About...

How Advanced Technologies Improves Clinical Trials

How Advanced Technologies Improves...

Why Create Patient Recruitment Strategies for Clinical Trials

Why Create Patient Recruitment...

Clinical Trials: Top Ways to Make Patient Recruitment Process More Efficient

Clinical Trials: Top Ways to Make...

Patient Recruitment: Some Excellent Strategies to Keep in Mind

Patient Recruitment: Some Excellent...

Celsion Corporation Introduces a Wholly-Owned Subsidiary to Develop ThermoDox

Life Sciences Review Life Sciences Review | Thursday, December 23, 2021
Tweet

Celsion GmbH oversees ongoing and future cancer research with ThermoDox®.


FREMONT, CA: Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, declares that its newly formed wholly-owned subsidiary, Celsion GmbH, will oversee all ongoing and future investigator-sponsored development of ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. Andreas Voss, M.D., a renowned oncologist, joins Managing Director of Celsion GmbH. Later this year, he will resign from Celsion's board of directors to lead the subsidiary based in Zug, Switzerland.


Celsion's management now focuses exclusively on GEN-1, DNA-mediated IL-12 immunotherapy in Phase I/II development for the treatment of advanced ovarian cancer, and PLACCINE", its nucleic acid vaccine platform. Celsions' ongoing investment in ThermoDox® will be limited to clinical drug supply and modest financial support.


ThermoDox® is currently being developed on an investigator-sponsored basis for a variety of cancer indications, including:


A Phase I study led by the University Medical Center Utrecht in the Netherlands to determine the safety, tolerability, and feasibility of ThermoDox® in combination with Magnetic Resonance Guided High Intensity Focused Ultrasound hyperthermia and cyclophosphamide therapy for the local treatment of metastatic breast cancer's primary tumor.


A Phase I study led by Oxford University in the United Kingdom will evaluate the intravenous administration of ThermoDox® in combination with High Intensity Focused Ultrasound in patients with pancreatic cancer.


The National Institutes of Health is conducting a clinical trial to evaluate ThermoDox® in combination with the chemotherapy drug mitomycin in patients with bladder cancer.


Commenting on his new role in leading Celsion GmbH, Dr. Voss says, “I am excited to spearhead this effort and to work with investigators around the world who are interested in pursuing further clinical development of ThermoDox®. Building upon encouraging preclinical results in several cancer indications, we have been fielding numerous requests from investigators to conduct their own studies. We know that doxorubicin is one of the most active cytotoxic drugs with no known specific resistance mechanism. Furthermore, the ability of ThermoDox® to deliver high doses into tumor tissue is proven and its mechanism of action is well understood. Celsion GmbHs long-term objective is to seek partnerships that will maximize the potential of ThermoDox®, ultimately providing value to the parent company.”


Michael H. Tardugno, Celsions chairman, president, and chief executive officer, says, “Despite the bitter disappointment and surprise with our Phase III OPTIMA study of ThermoDox® in primary liver cancer, many investigators are undaunted by various anomalies related to that data and see value in the drugs continued study. We owe patients and the scientific community the opportunity to investigate ThermoDox® while removing the financial obligation from our stockholders. Celsion is now solely focused on the significant opportunity we face with GEN-1 and PLACCINE in advanced ovarian cancer and SARS-CoV-2 vaccines, respectively. I am delighted that Celsion GmbH is in the experienced hands of Dr. Voss, who will pursue other collaborations and partnerships with the intent to monetize this asset.”


Weekly Brief

loading
Top 10 Biotech Startups in APAC - 2022
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing
Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/celsion-corporation-introduces-a-whollyowned-subsidiary-to-develop-thermodox-nwid-438.html